Companies·2 min read
By BitsMindsSource: TechCrunch

Google to Invest Up to $40 Billion in Anthropic, Doubling Down on Claude

Google commits $10 billion now and up to $30 billion more in milestone-based funding, on top of a five-gigawatt cloud compute deal — its biggest bet yet on Anthropic.

Google to Invest Up to $40 Billion in Anthropic, Doubling Down on Claude
Share:

Google will invest up to $40 billion in Anthropic, the maker of Claude, in one of the largest single commitments to an AI lab on record. The deal, reported on April 24, includes $10 billion in cash now at a roughly $350 billion valuation, with another $30 billion contingent on Anthropic hitting performance milestones.

The investment lands just days after Amazon disclosed plans to put up to $25 billion of its own into Anthropic, underscoring how quickly the AI infrastructure arms race has escalated. Google previously held an estimated 14 percent stake in the startup after committing more than $3 billion across rounds dating back to 2023.

Beyond cash, Google Cloud has agreed to deliver five gigawatts of computing power to Anthropic over the next five years, with room to expand. The capacity is intended to ease what Anthropic has called "inevitable strain" on its infrastructure as enterprise, developer and consumer demand for Claude continues to surge.

Anthropic's annualized revenue has crossed $30 billion this month, up from roughly $9 billion at the end of 2025 — growth driven heavily by Claude Code's traction with developers. The company's implied secondary-market valuation recently brushed $1 trillion, eclipsing OpenAI on that measure.

For Google, the move spreads its AI bets across both its in-house Gemini program and a fast-rising rival — a hedge against any single lab dominating the frontier. For Anthropic, the dual backing of Amazon and Google secures the compute it needs to keep training successively larger Claude models without taking a single hyperscaler as its sole patron.

More on Claude

Evergreen coverage we keep current — start here.

Want AI news before everyone else?

The morning's most important AI stories, straight to your inbox. No fluff.

Related Articles

Vals — the benchmark vault An editorial still life of a deep teal steel vault with a copper combination lock, confidential evaluation papers and an AI processor on an ivory surface. The sealed vault represents test materials kept out of model training. The forty-million-dollar Series A is noted discreetly above the scene. All artwork is original vector geometry; the document markings are illustrative and do not represent actual test results. Original SVG illustration for BitsMinds. Article: https://www.bitsminds.com/news/vals-40m-series-a-confidential-ai-benchmarks. Vector only; no external resources. VALS THE BENCHMARK VAULT $40M / SERIES A EVALUATION CONFIDENTIAL BITSMINDS.COM PRIVATE TESTS. REAL CAPABILITIES.
Companies

Vals Raises $40M to Grade AI Models in Secret

Crusoe: capital for the physical infrastructure of AI An original editorial cutaway of a modular AI data centre at night. Eight illuminated racks stand behind an open structural frame, alongside cooling equipment and a transformer connected by an amber power route. The illustration presents the article's 3.9 billion dollar Series F and 30.9 billion dollar post-money valuation. Separate labels distinguish 1 gigawatt operational from more than 6 gigawatts of gross contracted capacity across Crusoe's platform. The building is an illustrative concept, not a technical drawing or an exact depiction of a Spark product; its rack count has no quantitative meaning. BitsMinds editorial vector artwork. Article: crusoe-3-9b-series-f-ai-factories. 18 September 2026. Self-contained SVG. Funding and capacity figures reproduced from the article. CRUSOE $3.9B SERIES F $30.9B POST-MONEY VALUATION AI FACTORY 1 GW OPERATIONAL 6+ GW CONTRACTED POWER → COMPUTE BITSMINDS.COM
Companies

Crusoe Raises $3.9B at $30.9B for Its AI Factories

Novo puts Claude Science into drug discovery CLAUDE SCIENCE BITSMINDS.COM
Companies

Novo Nordisk Puts Claude Science Into Drug Discovery